Koers MiMedx Group Inc OTC Bulletin Board
Aandelen
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 361 mln. 337 mln. | Omzet 2025 * | 406 mln. 378 mln. | Marktkapitalisatie | 1,02 mld. 950 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 45 mln. 41,9 mln. | Nettowinst (verlies) 2025 * | 55 mln. 51,21 mln. | EV/omzet 2024 * | 2,82 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,51 x |
K/w-verhouding 2024 * |
22,1
x | K/w-verhouding 2025 * |
16,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,68% |
Recentste transcriptie over MiMedx Group Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 61 | 27-01-23 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 05-07-23 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 02-07-20 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-19 |
M. Wilsey
CHM | Chairman | 71 | 19-06-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-22,96% | 122 mln. | |
-21,75% | 58,45 mln. | |
+0,14% | 57,71 mln. | |
-4,19% | 50,39 mln. |